FDA requires rare vision-loss warning for GLP-1 drugs
publishers 41articles 42first reported 9 Nov, 12:00 UTCdeveloping since 9 Nov · 7 editions
The U.S. Food and Drug Administration is requiring makers of GLP-1 drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, to add warnings about a potentially increased risk of a rare eye condition that can cause permanent vision loss.
The condition, non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when reduced blood flow damages the optic nerve. Sometimes called an “eye stroke,” it can cause painless, abrupt vision loss, blurred vision, blind spots or distorted colors, often in one eye. The FDA advised patients who experience visual changes while taking a GLP-1 drug to contact a health care professional immediately.
The agency said NAION has been reported with all currently marketed GLP-1 receptor agonists. Its review included adverse-event reports and clinical studies involving more than 125,000 patients. The FDA found about six cases annually per 100,000 people taking GLP-1 drugs, compared with fewer than four per 100,000 among people receiving a placebo or other diabetes medications.
The absolute risk appears small, and whether the drugs directly cause the condition remains uncertain. Several NAION risk factors—including diabetes, cardiovascular disease, high blood pressure and sleep apnea—are also common among patients prescribed GLP-1 drugs.
Novo Nordisk said the available data do not establish a cause-and-effect relationship and that it remains confident in its medicines’ benefit-risk profile. Eli Lilly said it was reviewing the FDA update and would continue evaluating reports of eye-related events.
HOW THIS STORY WAS MADE
Written from 8 articles, 4 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 48 h after the record first saw the story; the editor kept it as written.
- Publishers
- 41
- Source articles
- 42
- Given to the writer
- 8, 4 with the article's own text
- Independent newsrooms
- 8
- This version written
- 48 h after the record first saw the story
- Second model (editor)
- kept as written
- Publication gate
- passed
- Human review
- none
WHAT THE EDITOR DID
The second model checked the writer's draft against the same sources and published it as written.
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →